These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 15765372)

  • 1. Evolving role of positron emission tomography in breast cancer imaging.
    Eubank WB; Mankoff DA
    Semin Nucl Med; 2005 Apr; 35(2):84-99. PubMed ID: 15765372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future uses of positron emission tomography in breast cancer imaging.
    Eubank WB; Mankoff DA
    Semin Nucl Med; 2004 Jul; 34(3):224-40. PubMed ID: 15202103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorodeoxyglucose-PET in the management of breast cancer.
    Kumar R; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1113-22, ix. PubMed ID: 15488561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET imaging in breast cancer.
    Bombardieri E; Crippa F
    Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET Imaging of Breast Cancer: Role in Patient Management.
    Lebron L; Greenspan D; Pandit-Taskar N
    PET Clin; 2015 Apr; 10(2):159-95. PubMed ID: 25829085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer.
    Siggelkow W; Rath W; Buell U; Zimny M
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S118-24. PubMed ID: 15146295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography in diagnosis and management of invasive breast cancer: current status and future perspectives.
    Wu D; Gambhir SS
    Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S55-63. PubMed ID: 12756080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future use of positron emission tomography (PET) in breast cancer.
    Mankoff DA; Eubank WB
    J Mammary Gland Biol Neoplasia; 2006 Apr; 11(2):125-36. PubMed ID: 17075687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
    Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
    Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a role for positron emission tomography in breast cancer staging?
    Hodgson NC; Gulenchyn KY
    J Clin Oncol; 2008 Feb; 26(5):712-20. PubMed ID: 18258978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography.
    Bénard F; Turcotte E
    Breast Cancer Res; 2005; 7(4):153-62. PubMed ID: 15987467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer.
    Landheer ML; Steffens MG; Klinkenbijl JH; Westenberg AH; Oyen WJ
    Br J Surg; 2005 Nov; 92(11):1363-7. PubMed ID: 16187254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography and bone metastases.
    Fogelman I; Cook G; Israel O; Van der Wall H
    Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET.
    Eubank WB; Mankoff DA; Vesselle HJ; Eary JF; Schubert EK; Dunnwald LK; Lindsley SK; Gralow JR; Austin-Seymour MM; Ellis GK; Livingston RB
    Radiographics; 2002; 22(1):5-17. PubMed ID: 11796893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
    Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE
    Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
    Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
    J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.
    Kalff V; Duong C; Drummond EG; Matthews JP; Hicks RJ
    J Nucl Med; 2006 Jan; 47(1):14-22. PubMed ID: 16391182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to therapy in breast cancer.
    Avril N; Sassen S; Roylance R
    J Nucl Med; 2009 May; 50 Suppl 1():55S-63S. PubMed ID: 19380410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.